Search

1 to 10 of 710
Sort by

Library Entry
Pericardial effusion under nivolumab: case-reports and review of the literature

Nivolumab, a programmed death-1 (PD-1) inhibitor, is an immune checkpoint inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer and renal cell carcinoma. Immune-related adverse events are frequent under immunotherapies. Cardiotoxic side effects, initially...


Library Entry
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses from immune checkpoint inhibition in subsets...


Library Entry
Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma

Immune checkpoint inhibitors have improved clinical outcomes including survival in several malignancies but have also been associated with a range of immune-related adverse events (irAEs). Neurological irAEs are rare compared to the more typical skin, gastrointestinal, and endocrine toxicities,...


Library Entry
CAR-T cell therapy: a potential new strategy against prostate cancer

Prostate cancer (PCa) is one of the main causes of cancer-related death in men. In the present immunotherapy era , several immunotherapeutic agents have been evaluated in PCa with poor results, possibly due to its low mutational burden. The recent development of chimeric antigen receptor (CAR...


Web Page
JITC Digest October 2019

Inside this Issue: Letter from the Editor JITC Editor Picks Other Recent JITC ARTICLES Letter from the Editor Dear JITC Readers, I am pleased to share news of the launching of JITC’s very own Twitter handle (@JITCancer ). Managed by JITC’s very own editors, this new platform will...


Web Page
ESMO Congress 2019 Highlights

The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ESMO Congress 2019 held in Barcelona, Spain. SITC CONNECT Account A SITC Cancer Immunotherapy CONNECT account is required to view past meeting highlights. ...


Library Entry
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. The authors investigated the efficacy and safety of pembrolizumab in patients with metastatic ACC. They concluded that single-agent pembrolizumab has...


Library Entry
Clinical and immune profiling for cancer of unknown primary site

Immune checkpoint inhibitors (ICIs) confer a survival benefit in many cancer types. Given that the survival outcome for cancer of unknown primary site (CUP) remains poor, the authors investigated the potential of CUP for immunotherapy. The authors conclude that the survival outcome of CUP...


Library Entry
Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab

The authors present a case of sequential immune-related adverse events (irAEs) in a patient with metastatic melanoma treated with single-agent anti-programmed cell death-1 (PD-1) therapy, pembrolizumab. Although numerous cases of irAEs have been reported, sequential multi-organ involvement,...


Library Entry
Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis

Hypophysitis is a well-recognized immune-related adverse event in patients treated with immune checkpoint inhibitors for cancer. Some anterior pituitary hormones may recover; however, secondary adrenal insufficiency is usually permanent. This case documents an unusual recovery from secondary...